Latest news with #MRI-compatible
Yahoo
11-04-2025
- Business
- Yahoo
Undiscovered Gems in the US Market for April 2025
As the U.S. market navigates a landscape marked by tariff tensions and economic uncertainties, major indices like the Dow Jones Industrial Average are experiencing volatility, yet remain poised for potential weekly gains. In this climate of fluctuating investor sentiment and economic indicators, identifying promising small-cap stocks requires a keen eye for companies with strong fundamentals and resilience to macroeconomic pressures. Name Debt To Equity Revenue Growth Earnings Growth Health Rating Wilson Bank Holding NA 7.87% 8.22% ★★★★★★ Oakworth Capital 31.49% 14.78% 4.46% ★★★★★★ Cashmere Valley Bank 15.62% 5.80% 3.51% ★★★★★★ Omega Flex NA -0.52% 0.74% ★★★★★★ Solesence 33.45% 23.87% -3.75% ★★★★★★ Anbio Biotechnology NA 8.43% 184.88% ★★★★★★ FRMO 0.08% 38.78% 45.85% ★★★★★☆ Pure Cycle 5.11% 1.07% -4.05% ★★★★★☆ First IC 38.58% 9.04% 14.76% ★★★★☆☆ Reitar Logtech Holdings 31.39% 231.46% 41.38% ★★★★☆☆ Click here to see the full list of 286 stocks from our US Undiscovered Gems With Strong Fundamentals screener. Here we highlight a subset of our preferred stocks from the screener. Simply Wall St Value Rating: ★★★★★★ Overview: IRADIMED CORPORATION specializes in the development, manufacturing, marketing, and distribution of MRI-compatible medical devices and related accessories globally, with a market cap of $658.13 million. Operations: IRADIMED generates revenue primarily from its patient monitoring equipment segment, which accounts for $73.24 million. IRADIMED, a nimble player in the medical equipment sector, showcases promising growth potential with its debt-free status over five years and high-quality earnings. Trading at 57.8% below its fair value estimate, the company reported Q4 2024 sales of US$19.39 million, up from US$17.45 million the previous year, and net income of US$5.15 million compared to US$4.54 million a year ago. The firm recently increased its quarterly dividend to $0.17 per share and forecasts annual earnings growth of 12%, though it faces challenges due to reliance on FDA approvals and U.S.-centric revenue streams (85%). IRADIMED's growth hinges on the 3870 MR IV pump's market expansion and infrastructure investments. Click here to explore the full narrative on IRADIMED's strategic initiatives. Simply Wall St Value Rating: ★★★★★☆ Overview: Interface, Inc. designs, produces, and sells modular carpet products across various regions including the United States, Canada, Latin America, Europe, Africa, Asia, and Australia with a market capitalization of approximately $1.14 billion. Operations: Interface generates revenue primarily from its Americas segment, contributing $800.81 million, and the Europe, Africa, Asia, and Australia segment with $514.85 million. Interface, a notable player in the modular carpet industry, has been making strides with its innovative product launches and strategic initiatives. The company's net debt to equity ratio stands at 41.6%, which is considered high, yet it has successfully reduced this from 163.5% over five years. Interface's earnings grew by an impressive 99.6% last year, outpacing the industry average of 4.6%. Recent product expansions like the Trina Turk X FLOR collection have gained traction in both residential and commercial markets, suggesting strong demand for their unique designs. Despite challenges such as macroeconomic pressures and currency fluctuations, Interface remains focused on sustainability goals and operational efficiency improvements to drive future growth prospects. Interface's strategic investments in automation and sustainability aim to enhance operational efficiency and brand positioning; click here to explore the full narrative on Interface. Simply Wall St Value Rating: ★★★★★★ Overview: Univest Financial Corporation operates as the bank holding company for Univest Bank and Trust Co., with a market capitalization of $783.34 million. Operations: The primary revenue streams for Univest Financial come from its banking operations, which generated $249.75 million, followed by wealth management at $29.98 million and insurance services contributing $22.47 million. Univest Financial, a bank holding company with total assets of US$8.1 billion and equity of US$887.3 million, is trading at 51% below its estimated fair value. The company has a solid foundation with total deposits of US$6.8 billion and loans amounting to US$6.7 billion, backed by an appropriate bad loans ratio of 0.2%. With earnings growth outpacing the industry at 6.8%, Univest also boasts a sufficient allowance for bad loans at 671%. Recent share repurchases indicate confidence in its valuation, while primarily low-risk funding supports stability amidst macroeconomic challenges. Univest Financial is poised for 3% to 5% loan growth in 2025, driven by customer outlook and M&A activity. Click here to explore the full narrative on Univest Financial's growth prospects. Click this link to deep-dive into the 286 companies within our US Undiscovered Gems With Strong Fundamentals screener. Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports. Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGM:IRMD NasdaqGS:TILE and NasdaqGS:UVSP. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
14-03-2025
- Business
- Yahoo
Assessment of the $6.63 Billion Cochlear Implants Market, 2034: Emerging Markets, such as Asia-Pacific, Latin America and Africa, Present a Significant Growth Opportunity
Cochlear Implants Market Dublin, March 12, 2025 (GLOBE NEWSWIRE) -- The "Cochlear Implants Market - A Global and Regional Analysis: Focus on Patient Type, End User, and Region - Analysis and Forecast, 2024-2034" report has been added to global cochlear implants market, initially valued at $2.42 billion in 2023, is set to witness substantial growth, projected to surge to $6.63 billion by 2034, marking a remarkable compound annual growth rate (CAGR) of 9.02% over the period from 2024 to 2034. The cochlear implants market has shown robust growth in recent years and is poised to continue expanding, though the pace may vary under different conditions. The global cochlear implants market has been experiencing significant growth, fueled by advancements in hearing restoration technologies and the increasing prevalence of sensorineural hearing loss. According to the data published by the World Health Organization (WHO), over 430 million people worldwide suffer from disabling hearing loss, with this number expected to reach 700 million by 2050. Additionally, advancements in cochlear implant technology, such as AI-based sound processing, wireless connectivity, and MRI-compatible implants, have significantly improved patient outcomes, making these devices more effective and user-friendly. Governments and healthcare organizations worldwide are also supporting the market through favorable reimbursement policies and funding initiatives, increasing accessibility for both pediatric and adult patients. In 2023, North America dominated the global cochlear implants market; however, the Asia-Pacific region is expected to register the highest CAGR of 10.53% during the forecast period 2024-2034. high healthcare expenditure, advanced medical infrastructure, and strong government support for hearing loss treatment are a few factors driving the growth of the region. The increasing awareness about hearing restoration solutions, along with the rising adoption of bilateral cochlear implantation, further supports market growth. Moreover, an aging population and the rising prevalence of age-related hearing loss have fueled demand among older adults seeking cochlear implants to improve their quality of life. Key Market Players and Competition SynopsisThe companies profiled have been selected based on inputs gathered from primary experts, who have analyzed company coverage, product portfolio, and market penetration. Some prominent names established in this market are: Cochlear Limited Sonova Holding AG Zhejiang Nurotron Biotechnology Co. Ltd. (Nurotron) MED-EL Medical Electronics Industrial ImpactThe cochlear implants market has significantly influenced the healthcare landscape, driven by key players such as Cochlear Limited., Sonova Holdings AG, Amplifon, (GAES), and others. These companies have been at the forefront, providing cutting-edge products for cochlear the market has been further shaped by strategic collaborations, mergers, and R&D investments, which enable companies to expand their global presence and introduce innovative solutions. With the increasing focus on understanding tissue architecture and disease mechanisms, the competitive landscape of the cochlear implants market is dynamic, with innovation and customer-centric approaches driving differentiation and Developments in the Cochlear Implants Market In May 2024, Cochlear Limited completed the acquisition of Oticon Medical's cochlear implant business from Demant, integrating approximately 20,000 Oticon Medical cochlear implant customers into its operations. This strategic move aims to provide continued support and transition these customers to Cochlear's technology platform over time. In March 2023, MED-EL Medical Electronics introduced direct streaming for their cochlear implant patients. This feature, available in their new MED-EL cochlear implant systems, allows users to stream audio directly from compatible devices (such as smartphones) to their implants, improving sound quality and convenience. This innovation enhances accessibility and user experience for individuals with hearing loss. In November 2024, Cochlear Limited launched the Nucleus 8 Sound Processor, featuring enhanced connectivity for direct streaming from Apple and Android devices and improved hearing in noisy environments. This innovation aims to provide clearer sound and greater convenience for individuals with hearing loss. Demand - Drivers, Challenges, and Opportunities Market DriversRising Prevalence of Hearing Loss: The global prevalence of hearing loss is increasing at an alarming rate, driven by factors such as aging populations, excessive noise exposure, genetic predisposition, and untreated ear infections. According to the World Health Organization (WHO), over 1.5 million people worldwide currently experience some degree of hearing impairment, with this number expected to rise due to demographic and environmental factors. Additionally, increased awareness and early diagnosis are leading to a higher adoption of hearing aids and cochlear implants, addressing the needs of individuals with severe to profound hearing ChallengesHigh Cost of Devices and Surgery: Despite the benefits of cochlear implants, their high cost remains a significant barrier limiting market penetration, particularly in low- and middle-income countries. A single cochlear implant procedure (including the device, surgery, and rehabilitation therapy) can cost $50,000 to $100,000 in the U.S., and prices are similarly steep elsewhere. Without insurance or subsidies, this expense is prohibitive for most patients. In developing regions, the lack of affordability is a primary reason that so few people who need implants receive them. Globally, it's estimated that only about 5-10% of candidates who could benefit from a cochlear implant have one, largely due to cost and access issues. The result is a substantial unmet medical need, where millions continue to live with severe hearing loss because the up-front price of treatment is out of OpportunitiesIncreasing Adoption in Emerging Markets: Emerging markets present a significant growth opportunity for the cochlear implants market due to improving healthcare infrastructure, rising awareness of hearing loss treatments, and increasing disposable income. Countries in Asia-Pacific, Latin America, and Africa are witnessing a surge in demand for cochlear implants as governments and healthcare organizations work toward expanding access to advanced medical technologies. Additionally, initiatives like subsidized healthcare programs, insurance coverage expansion, and partnerships with global medical device companies are making cochlear implants more affordable and accessible. Market Segmentation for Cochlear Implants Market Segmentation 1: by Patient Type Adult Pediatric Adult Segment to Dominate the Cochlear Implants Market (by Patient Type)Based on patient type, the global cochlear implants market was led by the adult segment, which accounted for the largest share in 2023 and is expected to reach $4.28 billion by 2034, registering a CAGR of 8.55% during the forecast period 2024-2034. The rising prevalence of age-related hearing loss and increasing awareness of cochlear implantation as an effective treatment for severe-to-profound hearing impairment. With a growing global geriatric population, particularly in developed regions such as North America and Europe, the demand for cochlear implants among adults is increasing significantly. Additionally, with continued innovation in implant design, surgical techniques, and post-implantation rehabilitation, the adult segment is expected to maintain its dominance in the cochlear implant market in the coming 2: by End User Hospitals ENT Clinics Others Hospitals Segment to Dominate the Cochlear Implants Market (by End User)Based on end user, hospitals accounted for the largest share in 2023 and are expected to reach $4.18 billion by 2034, registering a CAGR of 8.71% during the forecast period 2024-2034. A key factor contributing to the market's dominance is the availability of advanced surgical infrastructure, ENT devices, skilled healthcare professionals, and post-operative rehabilitation services required for successful implantation. Hospitals serve as the primary point of care for both pediatric and adult patients, offering comprehensive diagnostic assessments, surgical implantation, and long-term audiological support. The presence of multidisciplinary teams, including ENT specialists, audiologists, speech therapists, and rehabilitation experts, ensures optimal patient outcomes, further driving preference for hospital-based cochlear implant procedures. Key Attributes Report Attribute Details No. of Pages 70 Forecast Period 2024-2034 Estimated Market Value (USD) in 2024 $2.8 Billion Forecasted Market Value (USD) by 2034 $6.63 Billion Compound Annual Growth Rate 9% Regions Covered Global For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Cochlear Implants Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Associated Press
11-02-2025
- Business
- Associated Press
Symphony Robotics Licenses New Robotics Technology to Fight Brain Tumors
Symphony Robotics has secured an exclusive worldwide license from Case Western Reserve University (CWRU) for a novel MRI-guided, magnetically actuated, flexible micro robotic arm technology. This groundbreaking system navigates non linear trajectories, enabling precise, micro-invasive surgeries with real-time image guidance. CWRU researchers and faculty have been instrumental in the development and advancement of this innovation. Symphony Robotics is now advancing the patents-pending technology, which combines micro-robotic arms, real-time computer vision, and state-of-the-art artificial intelligence. The initial focus is to provide neurosurgeons with enhanced capabilities for complex microsurgical procedures, targeting brain cancer—particularly Glioblastoma Multiforme (GBM)—as well as epilepsy. The ultimate goal is to reduce incision and craniotomy sizes to less than 4 millimeters, representing a tenfold reduction compared to current clinical norms. GBM is among the most aggressive and challenging brain cancers to treat. Existing surgical methods, such as craniotomies, are highly invasive, requiring large skull openings and posing significant risks, including trauma to healthy brain tissue and delays in follow-up treatments such as radiation, chemotherapy, or drug delivery. Other methods such as laser ablation only support a limited and partial treatment option. Symphony Robotics' flexible, non-linear micro robotic arm aims to enable extended and precise access to deep seated lesions while protecting surrounding eloquent tissue, offering the potential to improve outcome and quality of life for GBM patients. Symphony Robotics founder and CEO, Mordechai (Moty) Avisar, stated: 'Our technology will introduce unprecedented advancements in neurosurgery. The potential to enhance surgical precision and improve patient outcomes is truly groundbreaking. Neurosurgeons will be able to perform highly targeted procedures on deep-seated pathologies through significantly smaller surgical openings—down to the micro level—while navigating complex, geometrically dispersed pathologies with greater safety and accuracy.' Dr. Robert Louis of the Pickup Family Neurosciences Institute, Hoag Memorial Hospital in Newport Beach, California, commented: 'The micro-robotic arm's MRI-compatible maneuverability will allow neurosurgeons to perform complete ablations through a single micro-opening, even in lesions that are otherwise untreatable due to their location and/or shape. This innovation could reduce the insertion hole size from something akin to a coffee cup to that of a small stirring straw. Could craniotomies become obsolete? It certainly seems possible.' CWRU has spent over a decade developing the underlying micro robotic arm technology, supported by funding from the National Institutes of Health (NIH) and the National Science Foundation (NSF). The University plans to continue collaborating with Symphony Robotics on further development. Symphony's ultra-maneuverable micro-robotic technology is built on two proprietary advancements: leveraging the magnetic capabilities of MRI systems for non-linear navigation of the micro robotic arms and enabling real-time guidance with MRI's high resolution imaging. The company is preparing for nationwide testing in collaboration with leading partner product is not available for clinical use and has not been cleared for use by the US FDA. About Symphony Robotics Symphony Robotics (SR) is leading the development and commercialization, of an advanced, ultra-maneuverable surgical micro-robot designed to revolutionize neurosurgery, particularly for treating Glioblastoma Multiforme (GBM). The core of this technology is a non-linear, flexible micro-robotic arm capable of navigating through complex brain structures with unparalleled precision. This groundbreaking innovation integrates real-time, MRI-guided visualization with cutting-edge AI and computer vision, giving neurosurgeons enhanced control over delicate procedures. Symphony Robotics (SR) is leading the development and commercialization, of an advanced, ultra-maneuverable surgical micro-robot designed to revolutionize neurosurgery, particularly for treating Glioblastoma Multiforme (GBM). The core of this technology is a non-linear, flexible micro-robotic arm capable of navigating through complex brain structures with unparalleled precision. This groundbreaking innovation integrates real-time, MRI-guided visualization with cutting-edge AI and computer vision, giving neurosurgeons enhanced control over delicate procedures. SOURCE: Symphony Robotics Copyright Business Wire 2025. PUB: 02/11/2025 10:11 AM/DISC: 02/11/2025 10:12 AM
